# Rich Gliklich

> Rich Gliklich is a surgeon-scientist, serial founder and healthcare data executive whose career has centered on measuring what happens to patients outside the controlled frame of a clinical trial. He built Outcome Sciences from a Harvard-affiliated research unit, led it through its 2011 acquisition by Quintiles, spent time at General Catalyst, and founded OM1 in 2015. As OM1's founder and CEO and Harvard Medical School's part-time Leffenfeld Professor of Otolaryngology-Head and Neck Surgery, he has helped move patient registries, real-world evidence and predictive analytics from specialist concerns toward the center of clinical research.

- **Role:** Founder and CEO at OM1; Leffenfeld Professor of Otolaryngology-Head and Neck Surgery, Part-time, at Harvard Medical School
- **Organizations:** OM1, Harvard Medical School, Massachusetts Eye and Ear, Massachusetts General Hospital, Outcome Sciences, Quintiles, General Catalyst, Agency for Healthcare Research and Quality
- **Education:** BA in Molecular Biophysics and Biochemistry, Yale University, MD, Harvard Medical School, Charles A. Dana Scholar in Epidemiology and Health Services Research, University of Pennsylvania
- **Known for:** Founded and led Outcome Sciences, which served more than 2,500 healthcare organizations and was acquired by Quintiles in 2011., Senior editor of all four editions of AHRQ's Registries for Evaluating Patient Outcomes: A User's Guide., Principal investigator for the federally funded Outcomes Measures Framework, an effort to standardize outcomes measurement.

## Career timeline

- **1987** — Earned his MD from Harvard Medical School, later completing an otolaryngology residency and a facial plastic and reconstructive surgery fellowship.
- **1998** — Spun a Harvard-affiliated outcomes research operation into Outcome Sciences and became its founder, CEO and chairman.
- **2007** — Co-edited the first edition of AHRQ's Registries for Evaluating Patient Outcomes: A User's Guide.
- **2011** — Led Outcome Sciences through its acquisition by Quintiles and became a leader of the buyer's late-phase and outcomes business.
- **2013** — Stayed with Quintiles through its initial public offering and was named the inaugural Leffenfeld Professor at Harvard Medical School.
- **2014** — Joined General Catalyst as an XIR focused on healthcare companies.
- **2015** — Founded OM1 to combine deep real-world clinical data with analytics and predictive models.
- **2020** — Co-edited the fourth edition of the AHRQ patient-registry guide.
- **2021** — OM1 announced an $85 million financing to expand its data networks, registry work and AI platform.
- **2024** — Outlined OM1's work on automated data collection, digital phenotyping and real-world evidence in a series of Applied Clinical Trials interviews.
- **2025** — Appeared as OM1's CEO at ISPOR and discussed the next era of evidence generation in OM1's Behind the Insights series.

## Achievements

- Founded and led Outcome Sciences, which served more than 2,500 healthcare organizations and was acquired by Quintiles in 2011.
- Senior editor of all four editions of AHRQ's Registries for Evaluating Patient Outcomes: A User's Guide.
- Principal investigator for the federally funded Outcomes Measures Framework, an effort to standardize outcomes measurement.
- Named the inaugural Leffenfeld Professor of Otology and Laryngology at Harvard Medical School in 2013; his current title is Leffenfeld Professor of Otolaryngology-Head and Neck Surgery, Part-time.
- Founder and CEO of OM1, which announced an $85 million financing in 2021 for its real-world data networks and AI platform.
- Named inventor on patents covering medical outcomes systems, medical devices and healthcare AI methods.

## Latest updates

- **2026-06** — Joined a DIA 2026 panel on designing patient registries for decision-ready evidence, alongside Nancy Dreyer, Angela Dobes and Mike D'Ambrosio.
- **2026-04** — Participated in the Medical Device Innovation Consortium's Innovations in Evidence Summit as OM1's founder and CEO on a real-world evidence panel with FDA and industry experts.
- **2025-05** — Participated as OM1's CEO at ISPOR 2025, where the company presented research across several specialty datasets.
- **2025-04** — Discussed AI-assisted automation, passive data collection and the future of evidence generation in OM1's Behind the Insights series.
- **2025-03** — OM1's public company history reported a growing portfolio of AI technology patents, including work in digital phenotyping, explainability and outcomes measurement.
- **2024-10** — Explained how real-world evidence could inform point-of-care decisions and personalized treatment trajectories in an Applied Clinical Trials interview.

## Links

- Website: https://www.om1.com/
- LinkedIn: https://www.linkedin.com/in/rich-gliklich-8a75a8
- Twitter/X: https://x.com/Om1Inc
- Facebook: https://www.facebook.com/profile.php?id=61573205886660

---

Profile page: https://yespress.io/rich-gliklich
Published by YesPress — https://yespress.io
Last updated: 2026-09-27